Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 1.00 |
| ▸ | CNR2 | P34972 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.92 |
| ▸ | RGS12 | O14924 | 1/20 | 0.92 |
| ▸ | GMNN | O75496 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | TP53 | P04637 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.92 |
| ▸ | THPO | P40225 | 1/20 | 0.92 |
| ▸ | BLM | P54132 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Win-552122 SCHEMBL29611661 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL3680086 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL29361053 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL29410177 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL29381882 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL118531 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL31338445 | 0.98 | CNR1 (0.96) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL1517636 | 0.96 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL8071465 | 0.96 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL29496357 | 0.96 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | MGMT, NEFM, TP53 | CNR1 2351/4885CNR2 1823/4885ALDH1A1 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.